Rationale for irradiation of persisting oligo‐skeletal metastases to improve survival of metastatic neuroblastoma patients with a poor response to chemotherapy: A retrospective study

Lea Rossillon,Véronique Edeline,Laurentiu Agrigoroaie,Claudia Pasqualini,Pablo Berlanga,Stephanie Bolle,Christelle Dufour,Dominique Valteau‐Couanet

DOI: https://doi.org/10.1002/pbc.31350

2024-10-16

Pediatric Blood & Cancer

Abstract:Background Persistent metaiodobenzylguanidine (mIBG)‐positive skeletal metastases post induction in high‐risk neuroblastoma correlate with a poor outcome. The aim of this study was to investigate the potential rationale for a prospective randomized study evaluating the impact on event‐free survival of the irradiation of residual oligo‐skeletal metastases. Procedure Patients over 1 year with a stage M neuroblastoma treated between 2000 and 2020 at Gustave Roussy were identified. Patients with a positive mIBG scan at diagnosis and persistent skeletal metastases after high‐dose chemotherapy (HDC) were included. Data were retrospectively collected and mIBG scans reviewed by two nuclear medicine physicians. Results Persistent skeletal uptake after HDC was observed in 30/201 patients (15%). Four patients reached a complete response at the end of maintenance treatment and did not relapse (median follow‐up [FU] 8 years [1.8–11.8]), while two patients had progressive disease during maintenance. Among the 24 patients with persistent skeletal uptakes at the end of treatment, seven had a persistent response (median FU 8.2 years [4–15.6]). Median SIOPEN (International Society of Paediatric Oncology European Neuroblastoma) scores post consolidation and at the end of treatment were, respectively, 2 [1–6] and 2 [0–4] for patients with persistent responses compared to 4 [1–28] and 2 [1–17] for patients with progressive diseases. Median SIOPEN score at progression was 34 [2–56]. Conclusions Our study underlines that only a minority of patients had persistent skeletal mIBG‐positive scans after HDC. Recurrence mainly occurred in disease sites present at diagnosis that cleared with chemotherapy. On‐therapy control of the disease is the main challenge. These results highlight the complexity of conducting a randomized study exploring this strategy.

oncology,pediatrics,hematology